Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

April 5, 2022

- AACR Investor Event time change to 6:30 p.m. ET -
- 21st Annual Needham Virtual Healthcare Conference Presentation April 13th at 1:30 p.m. ET -

SEATTLE--(BUSINESS WIRE)--Apr. 5, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a company presentation at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th, 2022, at 1:30 p.m. ET/10:30 a.m. PT.

Alpine will host a virtual investor event on April 12th, 2022, at 6:30 p.m. ET, to coincide with the 2022 American Association for Cancer Research (AACR) Annual Meeting. The meeting will commence 30 minutes later than previously announced and will begin at 6:30 p.m. ET.

A live webcast of both events will be available online in the investor relations section of the company’s website at A replay of each presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit Follow @AlpineImmuneSci on Twitter and LinkedIn.

Investor Relations
Alex Sharif
Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc
[email protected]

Media Relations
Kelli Perkins
Red House
[email protected]

Source: Alpine Immune Sciences Inc.